Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adult men with locally advanced or metastatic prostate cancer scheduled to receive LHRH analogues. A patient who has completed an IPSS questionnaire in his last visit, before the start of LHRH analogues, will be able to participate in the study. This last visit has to be done 6 months before the baseline visit.
Patients having provided written informed consent
Patients mentally fit for completing a self-administered questionnaire
You may not be if
Any surgical or radiotherapy treatment performed at prostate level before the entry of the study
Patient with castrate levels of testosterone ( \< 50 ng/dL) at his first IPSS questionnaire
Patients who are also participating in any other clinical study within the last 2 months before study entry
Life expectancy of less than 12 months
Clareo Health | Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
